Cite
Willis SE, Winkler C, Roudier MP, et al. Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. Br J Cancer. 2021;125(12):1666-1676doi: 10.1038/s41416-021-01560-1.
Willis, S. E., Winkler, C., Roudier, M. P., Baird, T., Marco-Casanova, P., Jones, E. V., Rowe, P., Rodriguez-Canales, J., Angell, H. K., Ng, F. S. L., Waring, P. M., Hodgson, D., Ledermann, J. A., Weberpals, J. I., Dean, E., Harrington, E. A., Barrett, J. C., Pierce, A. J., Leo, E., & Jones, G. N. (2021). Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. British journal of cancer, 125(12), 1666-1676. https://doi.org/10.1038/s41416-021-01560-1
Willis, Sophie E, et al. "Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response." British journal of cancer vol. 125,12 (2021): 1666-1676. doi: https://doi.org/10.1038/s41416-021-01560-1
Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P, Rodriguez-Canales J, Angell HK, Ng FSL, Waring PM, Hodgson D, Ledermann JA, Weberpals JI, Dean E, Harrington EA, Barrett JC, Pierce AJ, Leo E, Jones GN. Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. Br J Cancer. 2021 Dec;125(12):1666-1676. doi: 10.1038/s41416-021-01560-1. Epub 2021 Oct 18. PMID: 34663950.
Copy
Download .nbib